Caring Brands
Licenses and sells topical dermatology, hair-adjunct, suncare, and OTC wellness products.
Something off on this page? Send us feedback.
Profile
Commercializes and licenses topical dermatology, hair-growth-adjunct, suncare, and OTC-wellness products through U.S. e-commerce and international partners. A small, single-segment portfolio combines direct sales with licensing royalties and relies on intellectual property, partner execution, and regulatory compliance.
Commercializes and licenses a small portfolio of patented or patent-pending topical dermatology, hair-growth-adjunct, suncare, and OTC-wellness products. Hair Enzyme Booster is a topical adjunct to FDA-approved minoxidil; Photocil, marketed as PhotoFirst in India, is a UV filter used alongside care for psoriasis, vitiligo, and atopic dermatitis; Emesyl is a licensed homeopathic nausea-relief product. CB-101 and a reformulated NoStingz sunscreen remain in the pipeline.
Sells in the United States through e-commerce and pursues international commercialization through licensees, including partners for Hair Enzyme Booster and Photocil. Its operating method pairs established mechanisms with controlled clinical testing, patent protection, and commercial-stability work. It has a single reportable segment and a three-person team; product commercialization depends on external manufacturing, distribution, territory partners, regulatory and labeling compliance, and minoxidil use for Hair Enzyme Booster.
Company facts
Key statistics
Year to date +39.0% · Average volume (30d) 70.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | — | −$0.10 | — | — | — | — | −5.76% |
| Jun 30, 2026Q1 FY26 | — | −$0.29 | — | — | — | — | +14.52% |
| Mar 31, 2026Q4 FY25 | — | −$0.29 | — | — | — | — | −4.39% |
Financial highlights
| 3 quarters | — | — | — | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $740 | $420 | $0 | |
| Gross profit | — | — | — | $448 | $239 | $0 | |
| Operating income | — | — | — | −$999.5K | −$3.7M | −$1.7M | |
| Net income | — | — | — | −$1.0M | −$4.1M | −$2.0M | |
| Diluted EPS | — | — | — | −$0.08 | −$0.28 | −$0.27 | |
| Gross margin | — | — | — | 60.5% | 56.9% | — | |
| Operating margin | — | — | — | -135,064.2% | -889,672.4% | — |
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $0 · Total assets $1.9M · Shareholders' equity $1.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 9.09M · Float 1.04M · 11.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Wells Fargo & Company/MN | 72.4K | 0.80% | 13F | Jul 8, 2026 |
| Geode Capital Management, LLC | 58.8K | 0.65% | 13F | May 15, 2026 |
| Jane Street Group, LLC | 35.7K | 0.39% | 13F | May 12, 2026 |
| XTX Topco Ltd | 20.8K | 0.23% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 17.3K | 0.19% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Hims & Hers Health
DTC minoxidil and telehealth contest hair-loss customer acquisition.
- Incyte
Topical therapy in vitiligo and atopic dermatitis.
- Organon
Topical VTAMA addresses psoriasis and atopic-dermatitis treatment demand.
- Pfizer
Topical nonsteroidal eczema treatment contests future CB-101 positioning.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Caring Brands | $1.35 | −3.05% | $12.6M | — | — | 10,894.1 | — |
| Hims & Hers Health | $28.86 | +0.10% | $6.43B | — | 110.6 | 2.5 | +38.3% |
| Incyte | $124.37 | −0.03% | $25.21B | 15.8 | 43.0 | 4.3 | +37.7% |
| Organon | $13.76 | 0.00% | $3.61B | 17.9 | 3.9 | 0.6 | −2.3% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 17.9 | 26.5 | 2.5 | +20.2% |